Skip to main content
SpringerLink
Log in
Book cover

Transplantation in Hematology and Oncology II pp 253–262Cite as

First-Line and Salvage High-Dose Chemotherapy in Patients with Germ-Cell Tumors

  • Conference paper

  • 90 Accesses

Abstract

Most patients with metastatic germ-cell tumors (GCT) will be cured by platinbased combination chemotherapy followed by surgical resection of residual masses [1]. The outcome is considerably worse for patients with poor prognostic features at initial diagnosis, such as large tumor burden, multiple sites, extrapulmonary visceral metastases and/or high levels of tumor markers. These patients have a chance of cure of less than 50% with standard first-line treatment and must therefore be classified as “poor-prognosis” patients [2]. Furthermore, patients with an inadequate response to first-line chemotherapy or relapse from prior complete remission have also a considerably less favorable outcome as compared to other patients with GCT. Conventional-dose salvage chemotherapy in combination with resection of residual masses will result in second complete remissions in only about 30–60% of patients. In addition, at least half of these patients will suffer further relapses and will ultimately die of their disease. Depending on the presence or absence of adverse prognostic factors, only about 15–30% of patients overall will become long-term survivors after conventional-dose salvage chemotherapy [3, 4].

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bosl G, Motzer RJ (1997) Testicular germ-cell cancer. N Engl J Med 337:242–253.

    Article  PubMed  CAS  Google Scholar 

  2. International Germ Cell Cancer Collaborative Group (1997) International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15:594–603.

    Google Scholar 

  3. Harstrick A, Schmoll HJ, Wilke H, et al. (1991) Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J Clin Oncol 9:1529–1535

    Google Scholar 

  4. Loehrer PJ, Lauer R, Roth BJ, et al. (1988) Salvage therapy in recurrent germ cell cancer: Ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 109:540–546

    PubMed  Google Scholar 

  5. Bokemeyer C, Kollmannsberger C, Meisner C, et al. (1999) First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis. J Clin Oncol 17:3450–3456.

    PubMed  CAS  Google Scholar 

  6. Rick O, Bokemeyer C, Beyer J, et al. (2001) Salvage treatment with paclitaxel, ifosfamide and cisplatin (TIP) plus high-dose carboplatin, etoposide and thiotepa (CET) followed by autologous stem cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 19:81–88.

    PubMed  CAS  Google Scholar 

  7. Einhorn LH (1990) Treatment of testicular cancer: a new and improved model. J Clin Oncol 8:1777–1781.

    PubMed  CAS  Google Scholar 

  8. Birch R, Williams S, Cone A, et al. (1986) Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 4:400–407.

    PubMed  CAS  Google Scholar 

  9. Bower M, Newlands ES, Holden L, et al. (1997) Treatment of men with metastataic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. Ann Oncol 8:477–483.

    Article  PubMed  CAS  Google Scholar 

  10. Kaye SB, Mead GM, Fossa SD, et al. (1998) Intensive induction sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor prognosis metastatic nonseminomatous germ cell tumor: A randomized Medical Research Council/European Organization for Researche and Treatment of Cancer study. J Clin Oncol 16:692–701.

    PubMed  CAS  Google Scholar 

  11. Culine S, Theodore C, Bekradda M et al. (1997) Experience with bleomycin, etoposide, cisplatin (BEP) an alternating cisplatin, cyclophosphamide, doxorubicin (CISCA(II))/vinblastine, bleomycine (VB (IV)) regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors. Am J Clin Oncol 20:184–188.

    Article  PubMed  CAS  Google Scholar 

  12. de Wit R, Stoter G, Sleijfer DT, et al. (1995) Four cycles of BEP versus an alternating regimen and PVB and PEB in patients with poor prognosis metastatic testicular non-seminoma: A randomized study of the EORTC-Genitourinary Tract Cancer Cooperative Group. Br J Cancer 71:1311–1314.

    Article  PubMed  Google Scholar 

  13. Williams S, Birch R, Einhorn LH, et al. (1987). Treatment of disseminated germ cell tumors with cisplatin, bleomycin and either vinblastin or etoposid. New Engl J Med 316:1435–1440.

    Article  PubMed  CAS  Google Scholar 

  14. Chevreau C, Droz JP, Pico JL, et al. (1993). Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours: Preliminary results of a French randomized trial. Eur Urol 23:213–217.

    PubMed  CAS  Google Scholar 

  15. Motzer RJ, Mazumdar M, Bajorin DF, et al. (1997). High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 15:2546–2552.

    PubMed  CAS  Google Scholar 

  16. Bokemeyer C, Harstrick A, Beyer J, et al. (1998). The use of dose-intensified chemotherapy in th treatment of metastatic nonseminomatous testicular germ cell tumors: German Testicular Cancer Study Group. Semin Oncol 25:24–32.

    PubMed  CAS  Google Scholar 

  17. Bosl GJ, Geller NL, Cirrincione C, et al. (1983). Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 43:3403–3407.

    PubMed  CAS  Google Scholar 

  18. Medical Research Council (1985). Prognostic factors in advanced non-seminomatous germcell testicular tumours: Results of a multicentre study. Lancet 1:8–12.

    Google Scholar 

  19. Stoter G, Sylvester R, Sleijfer DT, et al. (1987). Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: Results from an EORTC multiinstitutional phase III study. Cancer Res 47:2414–2418.

    Google Scholar 

  20. Droz JP, Kramer A, Ghosn M, et al. (1988). Prognostic factors in advanced nonseminomatous testicular cancer. Cancer Res 43:3403–3407.

    Google Scholar 

  21. Aass N, Klepp O, Stahl-Cavallin E, et al. (1991). Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: A multicentre experience. J Clin Oncol 9:818–826.

    PubMed  CAS  Google Scholar 

  22. Bokemeyer C, Beyer J, Metzner B, Rüther U, Harstrick A, Weissbach L, Köhrmann U, Verbeek W, Schmoll HJ (1996) Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 7:31–34.

    Article  PubMed  CAS  Google Scholar 

  23. Motzer RB, Sheinfeld J, Mazumdar M, et al. (2000) Paclitaxel, ifosfamide, and cisplatin secondline therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 18:2413–2418.

    PubMed  CAS  Google Scholar 

  24. Motzer RJ, Mazumdar M, Sheinfeld J, Bajorin DF, Macapinlac HA, Bains M, Reich L, Flombaum C, Mariani T, Tong WP, Bosl GJ (2000) Sequential dose-intensive paclitaxel, ifosfamide, carboplatin and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 18:1173–1180.

    PubMed  CAS  Google Scholar 

  25. Beyer J, Bokemeyer C, Schmoll HJ, Siegert W (1994) Treatment intensification in disseminated germ-cell tumors. World J Urol 12:207–213.

    Article  PubMed  CAS  Google Scholar 

  26. Miller KD, Loehrer PJ, Gonin R, Einhorn LH (1997) Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol 15:1427–1431.

    PubMed  CAS  Google Scholar 

  27. Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH (1998) Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16:2500–2504.

    PubMed  CAS  Google Scholar 

  28. Rick O, Siegert W, Beyer J (1999) High-dose salvage chemotherapy. Germ-cell tumor treatment results in Germany. Int J Cancer 83:839–840.

    Article  PubMed  CAS  Google Scholar 

  29. Rodenhuis S, de Wit R, de Mulder PHM, Keizer HJ, Sleijfer DT, Lalisng RI, Bakker PJM, Mandjes I, Kooi M, de Vries EGE(1999) A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission. Ann Oncol 10:1467–1473.

    Article  PubMed  CAS  Google Scholar 

  30. Beyer J, Kramar A, Mandanas R, Linkesch W, Greinix A, Droz JP, Pico JL, Diehl A, Bokemeyer C, Schmoll HJ, Nichols CR, Einhorn LH, Siegert W (1996) High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic factors. J Clin Oncol 14:2638–2645.

    PubMed  CAS  Google Scholar 

  31. Saxman SB, Nichols CR, Einhorn LH (1994) Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: the Indiana University experience. J Clin Oncol 12:1390–1393.

    PubMed  CAS  Google Scholar 

  32. Fossa SD, Stenning SP, Gerl A, Horwich A, Clark PI, Wilkinson PM, Jones WG, Williams MV, Oliver RT, Newlands ES, Mead GM, Cullen MH, Kaye SB, Rustin GJS, Cook PA (1999) Prognostic factors in patients progressing after platinum-based chemotherapy for malignant nonseminomatous germ cell tumours. Br J Cancer 80:1392–1399.

    Article  PubMed  CAS  Google Scholar 

  33. Rick O, Beyer J, Schwella N, et al. (2001). Amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor, submitted

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin m.S. Hämatologie/Onkologie, Universitätsklinikum Charité, Campus Virchow-Klinikum, Humboldt Universität, Berlin

    O. Rick & W. Siegert

  2. Klinik für Innere Medizin m.S. Hämatologie/Onkologie, Klinikum der Philipps Universität, Marburg

    J. Beyer

Authors
  1. O. Rick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Siegert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Beyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Internal Medicine Hematology/Oncology, University of Münster, Albert-Schweitzer-Straße 33, 48129, Münster, Germany

    W. E. Berdel Prof. Dr. med. , Th. Büchner Prof. Dr. med.  & J. Kienast Prof. Dr. med. ,  & 

  2. Department of Pediatrics Hematology/Oncology, University of Münster, Albert-Schweitzer-Straße 33, 48129, Münster, Germany

    H. Jürgens Prof. Dr. med. , J. Ritter Prof. Dr. med.  & J. Vormoor Dr. med. ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Rick, O., Siegert, W., Beyer, J. (2003). First-Line and Salvage High-Dose Chemotherapy in Patients with Germ-Cell Tumors. In: Berdel, W.E., Büchner, T., Kienast, J., Jürgens, H., Ritter, J., Vormoor, J. (eds) Transplantation in Hematology and Oncology II. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-55774-3_31

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-55774-3_31

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-62660-9

  • Online ISBN: 978-3-642-55774-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation